Last reviewed · How we verify
ATM FOG in PD
ATM FOG is a fog inhalation formulation designed to deliver atomoxetine or a related compound directly to the lungs for potential neuroprotective effects in Parkinson's disease.
ATM FOG is a fog inhalation formulation designed to deliver atomoxetine or a related compound directly to the lungs for potential neuroprotective effects in Parkinson's disease. Used for Parkinson's disease (phase 3).
At a glance
| Generic name | ATM FOG in PD |
|---|---|
| Sponsor | Medical University of South Carolina |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
The exact molecular mechanism is not publicly detailed, but the formulation approach suggests delivery of a neuroactive compound via inhalation to achieve local or systemic effects relevant to Parkinson's pathology. The 'FOG' designation likely refers to a fog or aerosol delivery system intended to optimize bioavailability and brain penetration.
Approved indications
- Parkinson's disease (phase 3)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATM FOG in PD CI brief — competitive landscape report
- ATM FOG in PD updates RSS · CI watch RSS
- Medical University of South Carolina portfolio CI